Member Info for Moneymunch

Current roles available Project Manager Principal Scientist Senior Scientist Senior Software Engineer Product Development Engineer

A very good sign imho...Gla ;-) Microsaic ‏ @Microsaic 2h2 hours ago We're recruiting scientists and engineers! See our careers page: http://www.microsaic.com/careers/ #massspec #biologics #bioprocessing 0 replies 1 retweet 1 like

Lol, i'm still here and intend to hold for disclosure of Microsaic's global biopharma and subsequent productisation and commercialisation thereafter...in the meantime positive news could drop at anytime...trading statement, TR1, technology development and or contract news...a sudden and significant re-rate more than likely. Gla ;-)

Lol....get real....mostly buys this morning to drive the sp and a handful of sells later as a few took some profit....Higher highs and higher lows....the momentum is definitely upwards and the next wave of buyers will push the sp to new highs....5p plus this week still looks likely imho...Gla holders;-)

The last phase of the collaboration agreement with their global biopharma partner ran from April 2017 to December 2017 and a new extended research agreement was signed on 13/12/17 and is expected last into H2 2108, and so maybe another 8 month phase of collaboration.....the exciting part is that Microsaic's technology is already being integrated into their partners equipment and that the technology is already validated by their customers BIG pharma end-users, and so productisation and commercialisation almost looks guaranteed at this stage of proceedings imho ( hence the market reaction and increase in investor sentiment and interest ) and confirmation and disclosure of their global biopharma in the coming months will be a game changer for all invested.....in the meantime the upward momentum in sp will continue in anticipation imho, especially given that so few shares are in free float , Microsaics's tiny market cap of only �7.6m, with c�3m cash in the bank and existing revenue streams from their instruments and consumables from their established customers and OEM's which are expected to be much improved during H2 2017....further positive news could drop at anytime , Trading Statement, TR1's, and further technology developments and contracts secured etc which will see the sp re-rate and re-rate imho in run up to disclosure of Microsaic's partner on successful trials .....Microsaic's prospects look very attractive and offer the potential for significant growth, and no doubt why Skyepharma ex CEO is happy to join the party at this exciting time in its development .....5p plus plus this week imho!!! Gl ;-)

Product News: Miniaturised Mass Spectrometer is Enhanced to Enable Real-Time Analysis of Proteins in Bioprocessing Applications 12 May 2017 Microsaic Systems plc, the developer of chip-based mass spectrometry (MS) instruments, has developed a novel technology to enable real-time analysis of proteins in bioprocessing applications, such as in the manufacture of biologic molecules (proteins, antibodies and peptides) for therapeutic and diagnostic uses. The new technology is a tool for rapidly desalting and purifying protein samples prior to their analysis using Microsaic�s 4000 MiD� MS instrument. This new technology has the potential to significantly accelerate the industrial purification of biologics. Glenn Tracey, Microsaic�s Chief Operating Officer, commented: �The benefits of Microsaic�s point of use MS technology, in combination with its patented innovation for on-line desalting, allows for the purification of the desired biomolecules in real time. In doing so, analysis times can be reduced from days or even weeks to minutes while offering the potential for significant savings on operational costs. Eight of the top ten selling drugs in 2016 were biologics and the trend for targeted biologic therapeutics is set to continue. Technologies that can accelerate and enhance their production therefore present an opportunity for Microsaic.� Mass spectrometry is a powerful technique which allows the effective implementation of �QbD� (Quality by Design), a key industry and regulatory driver for current and future production of biologics.

Please note. More articles may be available for subscribers only. Microsaic January 2018 There is often a dash for bombed out shares around the turn of the year. This year is the turn of Microsaic (MSYS; 3.8p), down from a float price of 47p in 2011. The company, which has developed the world�s smallest mass spectrometer, is a spinout from Imperial College.................. http://www.scsw.co.uk/searchresults.php?textfield=msys&ftype=

You might get that chance Phirpo, as i dare say there might be a few who will want to grab some profit from Friday's close at 4.2p, although with the undoubted upward trend in sp and the increase in investor interest and focus, any dip will be brief imho.....and if any unexpected positive news lands, then Microsaic's sp will fly.....5p plus this coming week regardless imho....Gl ;-)

5p plus this coming week looks nailed on imho...Gla ;-)

The overall mass analyzer is about 9.5 inches long, about one-quarter of the size of those used in conventional triple-quadrupole instruments, according to Steven Wright, the Microsaic scientist who led the development. The researchers demonstrated the analyzer�s abilities by coupling it to a liquid chromatograph and by using it to perform both single-stage and tandem mass spectrometry. Microsaic wants to use the mini analyzer for field applications such as food analysis, including the detection of pesticide residues on apples. �We�ve shown that we can detect pesticides at 10 ppb,� a desirable level of detection in pesticide monitoring, Wright says. But don�t expect to see a commercial instrument just yet. �There�s a great deal of system engineering to do,� Wright explains. �We have the core of the system. The physics works, and we�ve got the performance, but now we have to build a system around it.� https://cen.acs.org/articles/93/i10/Shrinking-Triple-Quadrupole-Mass-Spectrometer.html

Micosaic also have other products in the pipeline, as highlighted by the following extract from their Interim Results September 2017 and the following article from March 2015 which details the potential of their Quadrupole Mass Spectrometer which is presumably a few years further down the road in its development. Gl ;-) 28/9/17 Technological enhancements The Company has a compelling product development pipeline in support of its bioprocessing applications and in maintaining its leading position in miniaturised MS instruments and technologies. Such enhancements aim to further extend the mass range for biologics detection, and introduce new capabilities, such as on-line desalting, which allows for the purification of biomolecules in real time. In doing so, analysis times can be reduced from weeks to hours, which offers the potential for significant savings in operational costs of bioprocessing. The Company has also developed a working prototype of a miniaturised "triple quadrupole" instrument, and is welcoming interest from partners for further product development and channels to market for this technology, in life science applications. Volume 93 Issue 10 | p. 8 Issue Date: March 9, 2015 | Web Date: March 5, 2015 Shrinking The Triple Quadrupole Mass Spectrometer Instrumentation: Researchers develop the first miniature analyzer for mass spec�s quantitation workhorse The ion optics bench of a miniaturized triple quadrupole mass spectrometer. The first miniature triple-quadrupole mass analyzer is not much longer than a pencil. To uncover the molecular composition of samples outside the lab, researchers have been shrinking mass spectrometers to make them portable. Various mass analyzers�the components of the spectrometer that sort molecular fragments and send them into the detector�have already been miniaturized, including ion traps and single quadrupoles. But triple quadrupoles, the mass analyzers of choice for most quantitative mass spec applications, have not been miniaturized�until now. A team at Microsaic Systems, in Woking, En�gland, has developed the first mini triple-quadrupole mass analyzer (Anal. Chem. 2015, DOI: 10.1021/acs.analchem.5b00311). The work �marks important progress in mass spec miniaturization,� says R. Graham Cooks, a chemistry professor at Purdue University. �Almost all previous miniature mass spectrometers have used ion traps.� �The mass spectrometer for targeted compound quantitation is the triple quad, whether the application is environmental monitoring, food safety, clinical analysis, or whatever,� says Richard A. Yost, a chemistry professor at the University of Florida. �This is really the first commercial attempt to develop a practical small-sized and potentially field-deployable triple-quad platform.�

Obviously a glitch in their system which no doubt will get sorted.....in the meantime....Gla ;-) The momentum is definitely upwards, although with so few shares in circulation the sp will be volatile in both directions ( and so be prepared ) but no doubt there must be plenty who will have wished they'd held on to their shares over the last few weeks with the sp closing above 4p plus......there are only 181m shares in issue and the majority are held tightly by institutional investors and it's estimated that there maybe only 40m in free float....Microsaic's market cap is only �7.6m and it's reckoned they have c�3m cash in the bank, and they already have an existing revenue stream from their established customers and OEM's from the sale of instruments and consumables , which are anticipated to be much better than H1 2017 trading conditions, and so a positive trading statement on H2 2017 revenue streams will no doubt add value....their minaturised mass spectrometry technology appears to be cutting edge, which is highlighted by the research agreement with their global biopharma partner which is already validated by their partners BIG pharma end user customers, and so successful trials in the coming weeks and months and disclosure of their partner and subsequent productisation and commercialisation will be a game changer and will see the sp many multiples from its current low imho...the appointment of Peter Grant to the Board, Syepharma's ex CEO speaks volumes, he was instrumental in Skyepharma's stunning development and subsequent �440m merger with Vectura and must have many industry contacts and influence that could be highly beneficial to Microsaic's fortunes....their current prospects and potential are looking very attractive for some serious upside, with very little downside if all goes to plan imho and so i intend to be invested for the long term......Good luck. ;-)

Ho Ho Ho Ho.....as I said earlier...a positive trading update/statement will add further value...but the real upside...the multi-bag ahead...the prize that we are all awaiting, is what we're all looking forward to...Gla holders...On and Up!!! :-) Disclosure of Microsaic's global biopharma partner with their global reach, which is expected in the coming weeks and months, will see the sp many multiples of the current price on successful trials and commercialisation imho......in the meantime with so few shares in circulation and most held tightly...this will continue to re-rate and re-rate in anticipation...Gl ;-) 13th December 2017 Q&A with Glenn Tracey Chief Executive Officer at Microsaic Systems PLC (LON:MSYS) Microsaic Systems plc Q&A with Glenn Tracey Chief Executive Officer at Microsaic Systems PLC (LON:MSYS) Microsaic Systems PLC (LON:MSYS) Chief Executive Officer Glenn Tracey caught up with ************* for an exclusive interview to discuss the research agreement with a global biopharma partner, the meaning of a biopharmaceutical, the biologics market and why they are seeing the need for in-process mass spectrometry for biologics that perhaps they wouldn’t see for traditional drugs. Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that? A1: Yes, absolutely so I’ve got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture. I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product. So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can’t give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales. https://www.***************************/microsaic-systems-plc-qa-ceo-glenn-tracey-lonmsys-2/412742383

Certainly looks like that way..gl ;-) https://uk.advfn.com/p.php?pid=quote&symbol=L%5EMSYS

5p plus plus this coming week imho...Gla ;-)

Every chance we could get a positive trading statement/update soon on H2 2017 revenues and developments to add further value. Gla ;-) 28/9/17 "H2 2017 revenues from instruments and consumables are anticipated to be above H1 2017 based on current performance in Q3. " Technological enhancements The Company has a compelling product development pipeline in support of its bioprocessing applications and in maintaining its leading position in miniaturised MS instruments and technologies. Such enhancements aim to further extend the mass range for biologics detection, and introduce new capabilities, such as on-line desalting, which allows for the purification of biomolecules in real time. In doing so, analysis times can be reduced from weeks to hours, which offers the potential for significant savings in operational costs of bioprocessing. The Company has also developed a working prototype of a miniaturised "triple quadrupole" instrument, and is welcoming interest from partners for further product development and channels to market for this technology, in life science applications. Traditional markets The Company is committed to working with its current OEM partners in small molecule detection. These partnerships provide important insights about customer needs and technology enhancements, as well as the capabilities and robustness of the Company's MS instruments in a real-world environment. Although H1 2017 was a very challenging period for revenues we are pleased to see these increasing again through continued close relationships with our partners. H2 2017 revenues from instruments and consumables are anticipated to be above H1 2017 based on current Q3 performance. https://uk.advfn.com/stock-market/london/microsaic-MSYS/share-news/Microsaic-Systems-plc-Interim-Results/75741969

This will bounce Big in the coming days imho....Gla holders... Hold on tight and enjoy the ride!!! ;-)

Microsaic gets a mention. Gl ;-) 3 January 2018 Global Mass Spectrometry Market Size, Share, Development, Growth and Demand Forecast to 2022 � Healthcare Market Reports Healthcare Market Reports has been published the new research report today. It provides objective assessment of market opportunities with detailed analysis of healthcare industries. The global mass spectrometry market accounted for $4,948.3 million revenue in 2015, and it is expected to grow at a CAGR of 8.1% during 2016-2022. http://www.military-technologies.net/2018/01/03/global-mass-spectrometry-market-size-share-development-growth-and-demand-forecast-to-2022-healthcare-market-reports/

Lol 3rdtimelucky, i have no intention of selling any shares and will be holding all the way to disclosure of Microsaic's global biopharma partner with their global reach, which is expected in the coming weeks and months, by which time the sp will be many multiples of the current price on successful trials and commercialisation imho......in the meantime with so few shares in circulation and most held tightly...this will continue to re-rate and re-rate in anticipation...Gl ;-)

Perfectly poised for the next leg up.....5p plus to be tested in the next few days imho. gla ;-)